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medicines adherence for Europe: a delphi study
Wendy Clyne*, Simon White and Sarah McLachlanAbstract
Background: Non-adherence to prescribed medication is a pervasive problem that can incur serious effects on
patients’ health outcomes and well-being, and the availability of resources in healthcare systems. This study aimed
to develop practical consensus-based policy solutions to address medicines non-adherence for Europe.
Methods: A four-round Delphi study was conducted. The Delphi Expert Panel comprised 50 participants from 14
countries and was representative of: patient/carers organisations; healthcare providers and professionals;
commissioners and policy makers; academics; and industry representatives. Participants engaged in the study
remotely, anonymously and electronically. Participants were invited to respond to open questions about the causes,
consequences and solutions to medicines non-adherence. Subsequent rounds refined responses, and sought
ratings of the relative importance, and operational and political feasibility of each potential solution to medicines
non-adherence. Feedback of individual and group responses was provided to participants after each round.
Members of the Delphi Expert Panel and members of the research group participated in a consensus meeting
upon completion of the Delphi study to discuss and further refine the proposed policy solutions.
Results: 43 separate policy solutions to medication non-adherence were agreed by the Panel. 25 policy solutions
were prioritised based on composite scores for importance, and operational and political feasibility. Prioritised
policy solutions focused on interventions for patients, training for healthcare professionals, and actions to support
partnership between patients and healthcare professionals. Few solutions concerned actions by governments,
healthcare commissioners, or interventions at the system level.
Conclusions: Consensus about practical actions necessary to address non-adherence to medicines has been
developed for Europe. These actions are also applicable to other regions. Prioritised policy solutions for medicines
non-adherence offer a benefit to policymakers and healthcare providers seeking to address this multifaceted,
complex problem.
Keywords: Policy, Consensus, Delphi technique, Medication adherenceBackground
Many patients do not take prescribed medication as
advised [1]: the World Health Organisation [2] reports
that only around 50% of the general population in devel-
oped countries are adherent to long-term therapies.
Non-adherence can have a negative impact on the effi-
cacy of treatments, patient well-being and the use of
scarce healthcare resources [3,4]. The importance of
finding ways to increase adherence is highlighted by
Haynes and colleagues [5] in a systematic review of ad-
herence interventions: “Increasing the effectiveness of* Correspondence: w.clyne@mema.keele.ac.uk
School of Pharmacy, Keele University, Staffordshire ST5 5BG, UK
© 2012 Clyne et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the oradherence interventions may have a far greater impact
on the health of the population than any improvement in
specific medical treatments”.
However, this is not simply a matter of patients choos-
ing not to take medicines as prescribed (intentional
non-adherence) or experiencing difficulty with taking
medicines (non-intentional non-adherence), since there
are recognised to be a wide variety of factors that shape
the landscape within which patients take medicines
[6-8]. These range from factors that are concerned with
interactions with health professionals to those that are
related to broader societal issues [6]. The interplay be-
tween these factors is highly complex and no singletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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address all of these issues [6]. Over at least the last three
decades a vast but often contradictory body of literature
on medicines adherence has accumulated that bears tes-
timony to this [1,9]. As such, numerous gaps in know-
ledge remain and clear research-based evidence of how
to reduce non-adherence on a large scale remains
elusive. This suggests that a comprehensive and inte-
grated approach is required to developing an evidence-
informed strategy, which includes action at health policy
level within and across nations.
One approach that is recognised to be of value in deal-
ing with complex issues like this, where there are known
to be numerous highly complex and inter-related factors
involved and where uncertainties inevitably remain, is to
harness expert opinion through consensus building
[10-13]. The Delphi method [10] is used to ascertain ex-
pert opinion and build consensus through a series of
‘rounds’ of structured questioning with feedback at each
stage. The technique enables a wide range of expertise
on a particular issue to be collated and is ideally suited
to electronic group communication when participants
are widely geographically dispersed [14]. Participants re-
tain anonymity throughout the Delphi process to min-
imise the influence of identity in their responses. This
Delphi study, conducted as part of the European Com-
mission funded Ascertaining Barriers to Compliance Pro-
ject (ABC Project), was used to amass expert opinion on
the causes, consequences, and solutions to medication
non-adherence across Europe and develop consensus on
the relative importance, and operational and political
feasibility of potential solutions. In the absence of high-
quality, consistent research evidence regarding the efficacy
of adherence interventions, consensus evidence is a useful
and appropriate resource for policy formulation.
Methods
Study design
The Delphi study proceeded over a series of four rounds
held between January and June 2011. All rounds were
completed online using Survey Monkey software and
participants received feedback electronically via blind
carbon copied emails. A consensus meeting with ABC
project partners and members of the Delphi Panel took
place at the end of the study to further develop the pol-
icy solutions. Conduct of the study was compliant with
the Helsinki Declaration and the study received ethical
approval from Keele University Ethical Review Panel.
The Delphi expert panel
Purposive sampling ensured that potential participants
had expertise relevant to one or more of the five dimen-
sions of adherence in the World Health Organisation
model [2]. Panel members were sampled from thefollowing five stakeholder groups to ensure a broad
range of expertise: academic; healthcare commissioner
or policymaker; pharmaceutical industry representative;
patient, carer, or patient organisation; healthcare profes-
sional. European Medicines Agency representatives were
also invited to take part. Participants were nominated by
ABC Project researchers or identified through an exten-
sive internet-based search. 50 individuals from 14 coun-
tries participated in one or more rounds of the study.
There were 25 males and 25 females on the Panel. All
five stakeholder groups were represented on the Panel
and several Panellists belonged to more than one group.
The European Medicines Agency was also represented.
The Delphi rounds
Round 1
Three open-ended questions were presented to the Panel:
What do you think the reasons are why people do not take
their medicines as prescribed?; What do you think the
consequences are of medicines non-adherence?; What do
you think the solutions are to medicines non-adherence?
Participants were asked to write as much or as little as
they wished in response to each question.
For each of the three questions posed to the Panel in
Round 1, the researchers independently segmented each
panellist’s responses into a series of discrete statements.
Statements were then coded and assigned to emerging
categories in a series of refinements of the categorisa-
tion. Statements that were identical or very similar in
essence were collapsed to form a single statement. Valid-
ation of the categorisation process involved discussing the
features of each category to ensure distinctiveness, estab-
lishing agreement that category names reflected the state-
ments that they subsumed, and scrutinising statements
that were not initially placed in a category for congruence
with existing categories. Some statements were not cate-
gorised including general introductory text around the
subject, humorous remarks, and direct repetition of an
earlier statement within the participant’s response. The
researchers remained blind to the authorship of state-
ments throughout.
Round 2
All panellists received feedback on the Panel’s responses
to the three questions from Round 1 and instructions
for the next round. Round 2 focused on the Panel’s pro-
posed solutions to non-adherence from the first round
by inviting participants to agree, reject, or amend each
proposed solution and offer new solutions that had not
been advanced in Round 1.
An a priori criterion for refining the solutions speci-
fied that those rejected by more than 50 per cent of the
Panel should not be taken forward to Round 3. Where
amendments were proposed, data from Round 1 were
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suggested modifications that could be made without
changing the core meaning of statements.
Round 3
Participants received feedback about the Panel’s collect-
ive responses to Round 2 and were asked to rate the im-
portance, and operational and political feasibility of each
solution. Ratings were made on five-point Likert-type
scales, as shown in Table 1.
There are no definitive guidelines for establishing con-
sensus in Delphi literature. While some researchers have
suggested that 51% agreement among respondents can be
interpreted as indicating consensus [16,17], others have
adopted more stringent levels [18]. Prior to data collection
[11,19], we defined consensus as 75 per cent or more
responses falling within a two-point bracket on a response
scale [15,20]. For instance, if 75 per cent or more respon-
dents provided ratings of “3” (somewhat important) or “4”
(very important) on the importance scale for a particular
solution, this was deemed to represent consensus of the
Panel on the importance of that solution.
Round 4
The purpose of this round was to seek consensus for rat-
ings on which the Panel had not converged in Round 3, in
light of information about panellists previous ratings.
Panellists received the potential solutions to non-adherence
for which consensus had not previously been reached,
alongside the mean ratings of the Panel from the previous
round. Participants who had taken part in Round 3 were
also provided with a reminder of their own previous ratings
for the potential solutions. Participants were asked to re-
rate those particular dimensions for which consensus had
not been achieved. All participants were invited to com-
ment on their Round 4 ratings.
Means and standard deviations were calculated for all
ratings made across Rounds 3 and 4. To produce a set
of solutions to non-adherence that reflected the prior-
ities of the Panel, only those solutions considered to be
“very important” or “extremely important”, i.e., those
with an importance rating of 4.00 or higher, were taken
forward to the consensus meeting. Overall priority rat-
ings for these policy solutions were calculated by sum-
ming the mean importance score and the average of the
two mean feasibility scores for each solution.
The consensus meeting
A group of 40 Delphi panellists and ABC Project
researchers from 10 countries met at the Royal Society,
London in June 2011. All stakeholder groups from the
Delphi study were represented. The objective of this
meeting was to further develop the policy solutions
through group discussion. A plenary session at the endof the meeting enabled the chairs of each discussion
group to present key outcomes of the roundtable discus-
sions. The discussions were audio-recorded with partici-
pants’ consent.
The recordings of the plenary sessions were tran-
scribed verbatim and analysed by two researchers who
had not participated in the discussions. Key themes,
ideas, and recommendations for policy development
were extracted. The policy solutions were amended in
light of the recommendations for development that had
been agreed within participants’ discussions.
Results
Round 1
The three questions generated a total of 1,142 statements;
531 statements in response to question 1, 256 for question
2, and 355 statements in response to question 3, from
which 501, 244 and 343 statements, respectively, were
extracted for analysis. Summaries of responses by category
for each question are shown in Tables 2, 3, and 4.
Causes of non-adherence to medication
Approximately 43% of the causes of non-adherence con-
cerned aspects of patients’ behaviour, beliefs or character-
istics. These included forgetfulness, low health literacy,
and negative beliefs about medicines. Patients’ experience
and interpretation of treatment, such as perceptions of
feeling no benefit from treatment and, conversely, stop-
ping treatment when benefit was experienced, were also
perceived as causes of non-adherence. Medication itself
was a cause of non-adherence in nearly 20% of statements,
because of the complexity of medication regimens, poly-
pharmacy, the cost of medication for the patient, and side
effects. Overarching theories about the causes of medi-
cines non-adherence represented a significant minority of
statements. These often referred to the multiplicity of fac-
tors that together can result in non-adherence, and the
notion that medicines non-adherence can be intentional
and unintentional.
Consequences of non-adherence to medication
Panellists viewed the consequences of medication non-
adherence to be overwhelmingly, but not exclusively,
negative. Over half of the consequences listed by the
Panel were experienced directly by the patient, positive
or negative, through symptom experience, disease pro-
gression, quality of life, illness and death. A quarter were
experienced by the healthcare system, through waste of
money, medication and resources and increased utilisa-
tion of healthcare.
Although the consequences of medication non-adherence
were largely perceived as negative by the Panel, positive
consequences of medication non-adherence were also listed.
Positive consequences for patients included the avoidance
Table 1 Response scales used by the Delphi Panel for rating the importance, operational feasibility, and political
feasibility of solutions to medication non-adherence
Important scale Operational feasibility scale Political feasibility scale
1. Not at all important 1. Definitely unfeasible 1. Definitely politically unfeasible
− Unlikely to have impact on non-
adherence
− Cannot be implemented − Politically unacceptable
− Not at all confident about
effectiveness of solution
− Unprecedented allocation of resources would
be needed
− Completely unacceptable to the public
−Basic research needed
2. Slightly important 2. Probably unfeasible 2. Probably politically unfeasible
− Potential for impact on a minority of
patients
− Some indication that this cannot be
implemented
−Major political obstacles
−Not very confident about effectiveness
of solution
− Large scale increase in available resources would
be needed
− Not acceptable to a large proportion
of the general public
−Major research effort needed
3. Somewhat important 3. May or may not be implemented 3. May or may not be implemented
politically
− Potential for impact on some patients − Contradictory evidence that this can be
implemented
−Political obstacles
−Unsure about effectiveness of solution − Increase in available resources would be needed − Some indication that this may not be acceptable
to a large proportion of the general public
−Indeterminable research evidence
available
4. Very important 4. Probably feasible 4. Probably politically feasible
− Potential for impact on majority of
patients
− Some indication that this could be
implemented
− Some minor political obstacles
− Quite confident about effectiveness of
solution
− Available resources would have to be
supplemented
− Further consideration may have to be given
to public reaction, although some evidence exists that
the proposed solution may be acceptable
−Some research still required
5. Extremely important 5. Definitely feasible 5. Definitely politically feasible
− Potential for widespread general
impact
− Can be implemented − No major political obstacles
− Very confident about effectiveness of
solution
− Necessary resources (financial, labour etc) are
presently available
− Will be acceptable to the general public
− No further research required
The importance rating scale was adapted from Hardy et al. [15], while the feasibility scales were adapted from Adler and Ziglio [10].
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tient quality of life was also seen to benefit from medication
non-adherence through feeling that one is not dependent
on medication, and feelings of control and mastery.Solutions to non-adherence to medication
More than half of the solutions offered by panellists fo-
cused on achieving change in patients’ knowledge and
behaviour. There were nearly three times the number of
statements relating to changing or adapting patients’
knowledge and behaviour than those relating to chan-
ging or adapting healthcare professionals’ education and
behaviour. Solutions focusing on change at the health-
care system or government level together amounted to
less than 10% of the solutions generated by the Panel.A substantial proportion of statements by panel mem-
bers emphasised the need to improve patient education
and information about treatment to make the informa-
tion understandable, impartial, evidence-based, and in-
clusive of details of other forms of treatment. A similar
number of statements described improving education
and information about the administration of medication.
Several statements specified the need to improve educa-
tion and information on the potential side effects of the
medication, while others expressed the importance of
improving education and information to inform patients’
risk-benefit analysis.
A sub-set of solutions related to changes to medica-
tion, including simplification of the regimen, the devel-
opment of better drugs with reduced side-effects, and
improved packaging, and often referred to the tailoring
Table 2 Causes of medication non-adherence by category
Category Count %
Patient factors - patient behaviour/characteristics 100 20.0
Medication factors 98 19.6
Patient factors - treatment effects 66 13.2
Patient factors - patient beliefs and concerns 55 10.9
Clinician factors 42 8.4
Meta theories of adherence/ theories of adherence 42 8.4
Healthcare organisation factors 32 6.4
Patient/clinician interaction 29 5.8
Environmental and social/structural factors 28 5.6
Disease factors 9 1.8
Total 501
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the patient’s lifestyle.
Improving education and training for identifying and
assessing medication non-adherence was a prominent
solution for the Panel. A number of statements focused
on improving education and training in patient-centred
care to move away from a paternalistic approach to
patients. A large number of statements about the input
of healthcare professionals related to the provision of
ongoing feedback and support with medication-taking.
Frequently cited amongst the healthcare professional-
focused solutions was the importance of taking a non-
judgmental approach and ending the conception of
non-adherence as something that should be blamed on




Consequences for patients 125 51.2
Disease consequences 54
Medication consequences 46
Quality of life/well-being consequences 25
Consequences for healthcare professionals 6 2.5
Consequences for clinician-patient interaction 11 4.5
Consequences for the healthcare system 62 25.4
Waste of resources 52
Public health risk 10
Consequences for society 20 8.2
Waste of resources 14
Research/industry 6
Total 244healthcare professionals was the use of reviews of medi-
cation and included suggestions such as targeting
reviews towards patients on multiple medications or
complex regimens.
Solutions concerning clinician-patient interaction were
fewer in number than those relating to healthcare pro-
fessionals. Ensuring patient involvement and a partner-
ship approach between clinicians and patients, building
a partnership between doctors and patients, and the
provision of frequent opportunities for open discussion
with the patient about medication-taking were frequent
statements here. The need to discuss patients’ beliefs
about medications, the condition, and the likelihood of
taking medications was also expressed. Statements about
discussing patient preferences formed another category.
A small number of solutions referred to the impact of
the health system on adherence behaviour and these fell
into four categories. The first was a team approach to
treatment by healthcare professionals, for example, the
involvement of nurses and pharmacists, and the concept
of the ‘Medicines Education Team’. The second category
concerned financial investment for supporting adher-
ence. The last two categories within the scope of the
healthcare system are in opposition; while the larger of
the two contained statements about reducing the cost of
medications for patients through the development of re-
imbursement systems, removing prescription charges,
and lowering out of pocket costs for medication, the
other encompassed statements about financial penalties
for the non-adherent patient.
A few solutions related to government involvement in
adherence support. Three categories emerged: statements
relating to the investment of resources or money in medi-
cation adherence, particularly regarding education, re-
search, and access to medicines; increasing public
awareness of the issue of medication adherence, for in-
stance through public education campaigns and interven-
tions to improve health literacy; and suggestions for policy
development in the field of adherence, for example, elevat-
ing patient adherence as a critical healthcare issue.
Three overarching themes on solutions to non-
adherence emerged from the data. These were not solu-
tions but rather ‘meta-theories’ about the nature of
solutions to non-adherence. The most commonly cited
theme related to the complex nature of solutions and
the need for multifaceted interventions to achieve a
comprehensive response to non-adherence. Several
panellists also highlighted the lack of long-term effect-
iveness of current solutions to non-adherence, and the
absence of an evidence base for the effectiveness of ad-
herence interventions. The final theme was the need for
solutions to correspond to reasons for non-adherence,
for example, developing solutions matched to uninten-
tional or intentional causes of non-adherence.
Table 4 Solutions to medication non-adherence by
category
Solution Category Number %
Patient focused solutions 187 54.5
Educational/informational 107
Medication-related 39
Behavioural strategies to eradicate forgetfulness etc. 32
Involvement of the social network/caregivers can
supportpatients with medication adherence
6
Building the patient’s trust in the healthcare
professional would improve medication adherence
3
Healthcare professional focused solutions 69 20.1
Clinician-patient interaction focused solutions 43 12.5
Themes/theories relating to solutions 16 4.7
Health system solutions 14 4.1
Government focused solutions 14 4.1
Total 343
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For each of the 43 proposed solutions presented in
Round 2, the percentage of the Panel that agreed with,
rejected, or amended the solution was calculated. Two
solutions that did not meet our a priori criterion for in-
clusion were deleted (“A consistent size, shape, and
colour for medications throughout Europe, whoever the
manufacturer is, would improve medication adherence”
and “Financial penalties imposed on patients who are
non-adherent would address medication adherence”).Round 3
The Panel achieved consensus for 64 of the 126 ratings.
One solution was removed following feedback from
panellists: “Patients need to broadly adjust to their ill-
ness and treatment”. This solution represented a sug-
gestion put forward by one member of the panel in the
first round and was queried by a number of panellists
in Round 2. The Delphi research team therefore modi-
fied the wording of this solution to increase its clarity
in Round 3. However, as a consequence of the con-
cerns raised by several members of the panel with re-
gard to this recommendation, this item was excluded
from Round 4.Round 4
Means and standard deviations for the 60 ratings that
were made in Round 4 were calculated. The criterion
used for determining consensus in Round 3 was used in
Round 4 to determine consensus (75% of ratings falling
within a two-point bracket on the response scale). A
substantial shift towards convergence of ratings was
found, with 58 of the 60 ratings achieving consensus.Overall, 121 of the 123 ratings made across Rounds 3
and 4 achieved consensus.
Prioritised solutions were identified and ranked in a
two-step process. Only those solutions considered to be
“very important” or “extremely important” by the Expert
Panel (i.e., with a mean rating of 4.00 or higher) were
retained. The application of this criterion resulted in 25
policy solutions remaining in the final list. In order to
determine the level of priority of each of these 25
solutions, the importance and feasibility ratings were
combined in a single score by summing the mean im-
portance score and the average of the two mean feasibil-
ity scores for each solution, as shown in Table 5.
Consensus meeting
Minor amendments were made to the wording of policy
solutions on the basis of themes identified from tran-
scripts of final plenary statements at the consensus
meeting and from discussion with the wider ABC pro-
ject team. The resulting dissemination statement of
consensus-based policy solutions for medication adher-
ence is shown in Table 6.
Discussion
The Delphi panellists achieved consensus about a broad
range of policy solutions for Europe to address medica-
tion non-adherence, and agreed on the relative import-
ance and feasibility of those solutions. This consensus is
all the more significant having been obtained with parti-
cipants from fourteen countries from a diverse range of
stakeholder groups who might be expected to have di-
vergent perspectives, experiences and interests in medi-
cation adherence. Participation in a Delphi study demands
a significant commitment of time and effort over a num-
ber of months and the 1,142 separate statements made by
this Panel represent a significant resource.
Strengths and limitations
Many, but not all, of the solutions target action at the pa-
tient and the public, rather than policy interventions at the
healthcare provider or systems level. This may well corres-
pond with the Panel’s beliefs, reflected in the wider research
literature that the primary cause of non-adherence is
patient’s beliefs about illness and treatment [21,22]. Equally,
the majority of published adherence interventions are edu-
cational and behavioural interventions to change patient
behaviour rather than (potentially more challenging) inter-
ventions to change healthcare systems and culture [23].
When considering potential solutions to non-adherence,
panellists may have brought to mind those causes and
interventions for non-adherence with which they are most
familiar from research literature and practice, hence the
focus on patient-oriented solutions over other ways of
intervening to address medicines non-adherence.











1. Improve patient education and information when a medication is newly prescribed 8.92 4.47 4.39 4.50
2. Improve patient education and information focused on the patients’ treatment 8.42 4.13 4.16 4.42
3. Improve patient education and information regarding the benefits of adherence to
their particular medication(s)
8.40 4.11 4.24 4.34
4. Improve education and training for healthcare professionals about ways of addressing
medication non-adherence to drive improvements in clinical practice
8.32 4.42 3.86 3.93
5. The patients' preferences for treatment should be discussed to support medication
adherence
8.27 4.32 3.89 4.00
6. Improve education and training for healthcare professionals about patient-centred care 8.25 4.32 3.89 3.96
7. Improve patient education and information about potential side effects or adverse
effects and how to manage them
8.21 4.08 4.13 4.13
8. Healthcare professionals should support patients with concerns about or experience of
side effects of medication
8.18 4.18 3.96 4.04
9. Improve education and training for healthcare professionals about identifying and
assessing medication non-adherence to drive improvements in clinical practice
8.06 4.18 3.76 4.00
10. Ensure patient involvement and a partnership approach, for example in treatment
plans and decisions, to support medication adherence for those patients who wish to be
involved
8.05 4.32 3.66 3.79
11. Simplify the patients’ medication regimen (e.g., less frequent, modified formulation
and/or dosage, tailored to individual need)
8.05 4.16 3.82 3.96
12. Improve education and training for healthcare professionals regarding medication
adherence in general
8.03 4.05 3.95 4.00
13. Improve patient education and information to assist the patient to weigh up the
benefit and harm of medication
7.99 4.18 3.75 3.86
14. Increase public awareness of the issue of medication adherence 7.94 4.13 3.82 3.79
15. The patients' health- and medication-related beliefs should be discussed between the
clinician and the patient to support medication adherence
7.90 4.29 3.50 3.71
16. Healthcare professionals should use reviews of medication to discuss medication
adherence with patients
7.84 4.03 3.82 3.79
17. Healthcare professionals should provide the patient with ongoing feedback and
support with medication-taking
7.82 4.07 3.79 3.71
18. Stop medication(s) that the patient no longer needs or wants 7.81 4.00 3.75 3.86
19. Ensure a consistent team approach to treatment, in which all members of the
healthcare team work together to support medication adherence
7.61 4.21 3.18 3.61
20. Healthcare professionals should adopt a non-judgmental approach to the issue of
medication adherence
7.61 4.11 3.43 3.57
21. Build patients’ trust in the healthcare professional to support medication adherence 7.60 4.11 3.43 3.54
22. Information provision should be tailored to the individual preferences or needs of the
patient
7.56 4.03 3.34 3.71
23. Governments should implement evidence-based policies about medication
adherence
7.53 4.05 3.42 3.53
24. Governments should invest resources/money in medication adherence, particularly
regarding education, research, and access to medicines
7.39 4.11 3.34 3.21
25. Healthcare professionals should make sufficient time for the patient, for instance
through more frequent contact
6.79 4.00 2.76 2.82
* Higher ratings indicate higher priority; lowest possible priority rating = 2, highest possible priority rating = 10.
♦ Importance, operational feasibility, and political feasibility ratings were made on 5-point scales; higher scores indicating higher importance/feasibility.
Note. All ratings for the policy solutions listed in the table achieved consensus from the ABC Delphi Panel.
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to think about each potential solution, and in later
rounds, the importance and feasibility of each solution,in isolation. In practice, interventions to support medi-
cines adherence may be multi-faceted, delivered in paral-
lel, and cut across the categories used here to help
Table 6 ABC consensus-based policy solutions for
medication adherence for Europe
Patients benefit when provided with support, education, and
information
• when a medication is newly prescribed
• focused on the patients’ treatment
• about the benefits of adherence to their particular medication(s)
• about potential side effects or adverse effects and how to manage
them
• to assist the patient to weigh up the benefit and harm of medication
• tailored to the individual preferences or needs of the patient
Healthcare professionals should receive education and training
about
• patient-centred care
• identifying and assessing medication non-adherence
• ways of addressing medication non-adherence when it is identified
so that they can:
• adopt a non-judgmental approach
• identify medication non-adherence
• provide patients with ongoing feedback and support with
medication-taking
• support patients with concerns about, or experience of, side effects
of medication
• make sufficient time for the patient, for instance through more
frequent, timely contact
Together, healthcare professionals and patients should
• discuss the patients' preferences for treatment
• ensure a partnership approach in decision making and treatment
• discuss the patients' health- and medication-related beliefs
• build the patients’ trust in the healthcare professional
Regarding medicines
• simplify the patients’ medication regimen as appropriate (e.g., less
frequent, modified formulation and/or dosage, tailored to individual
need)
• stop medication(s) that the patient no longer needs or wants
Healthcare providers should
• promote a team approach, sharing information to deliver consistent
adherence support
• prioritise medication adherence support in service, organisation, and
systems design
Governments/healthcare payers should
• increase public awareness of medication adherence for all citizens
• develop and implement evidence-based interventions for medication
adherence
• provide training and guidance for all healthcare providers so they can
deliver effective adherence interventions
• invest in research to identify effective interventions demonstrating
value for money
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tell us how policy makers and commissioners might seek
to combine interventions for best effect or perhaps stag-
ger the introduction of individual solutions within an
overall implementation strategy.
The requirement for panellists to communicate in the
English language may have prevented some potential
panellists from participation. Panellists came from 14
different countries, though a significant minority of the
panel were UK based. Nevertheless, the policy solutions
represent the combined views of a diverse group of sta-
keholders with a remit for adherence, rather than the
views of a specific interest group or a single professional
group [24,25].
This study improves on previous research initiatives to
develop policy recommendations for medicines adher-
ence in several ways. The proposed solutions look be-
yond the actions and interactions that occur in the
clinical setting [7] to broader systems and process fac-
tors that impact on medicines adherence. Recommenda-
tions for policy to address medication adherence
identified here for Europe are similar in scope to policy
initiatives in the USA [26,27], which have also been
developed with multi-stakeholder input.
Comparison with other studies
Other research in this area, such as systematic reviews
of adherence interventions [5], tends to report that the
evidence for the effectiveness of adherence interven-
tions is either limited, short lived in duration of effect,
or both. Many adherence interventions in research
studies are complex and it can be difficult to tease
apart the active ingredients of the intervention. A chal-
lenge for healthcare policymakers is overcoming the
stark gap between interventions that are delivered as
part of clinical trials and the reality of what is possible
in clinical practice and within limited budgets. Our
study provides succour for the policy maker seeking ef-
fective solutions for medicines non-adherence that are
also feasible at an operational and political level. On
the latter point, the research evidence-base has little to
offer. In this regard our study may act as a guide for
evidence-informed implementation.
Conclusions
The solutions to medication non-adherence for Europe
are broad and practical in nature. The breadth of the
policy solutions enables significant flexibility in national
implementation to reflect differences in healthcare sys-
tems, health-related culture, available resources, and the
level and sophistication of existing implementation.
Local implementation of the highest priority item ‘im-
prove patient and education when a medication is newly
prescribed’ could, for example, be delivered in a number
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http://www.biomedcentral.com/1472-6963/12/425of ways: as part of a community pharmacy service such
as the New Medicines Service in England [28]; in con-
junction with a trial prescription programme such as
those in Canada [29]; or within the context of existing
services provided in primary care. The policy solutions
described in Table 6 have sufficient flexibility to incorp-
orate a number of implementation responses. Policy
recommendations for medication adherence for Europe
have been discussed at several dissemination events as
part of the ABC Project (further details at http://www.
abcproject.eu/) and we hope this paper stimulates fur-
ther discussion and action. Future efforts should focus
on sharing implementation practice to improve our
knowledge of the range of policy responses to medica-
tion non-adherence across Europe.
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